Ichor at forefront of Rejuvenation & Longevity drug R&D – Dr. Kelsey moody | 231

November 21, 2023

Dr. Kelsey Moody is a process-oriented biotechnology executive who has specialized in the study of aging and aging mechanisms for over a decade. Since 2013, He has successfully built Ichor from a living room start-up into a premier, vertically integrated contract research organization that focuses on pre-clinical research services for aging pathways. Proceeds from this work are used to self-fund R&D initiatives that constitute Ichor’s portfolio companies in enzyme therapy (Lysoclear, Inc.), small molecule drug discovery (Antoxerene, Inc.), and protein engineering (RecombiPure, Inc.). Kelsey has received graduate-level training in medicine, business, and laboratory research.

Newsletter sign up (new and exciting developments)

https://learningwithlowell.us12.list-manage.com/subscribe?u=08ed8a56013d8b3a3c01e27fc&id=6ecaa9189b

Join this channel to get access to perks: https://www.youtube.com/channel/UCzri06unR-lMXbl6sqWP_-Q/join

Over 321 books from 170 plus interviews over 5 years

PODCAST INFO:

The Learning With Lowell show is a series for the everyday mammal. In this show we’ll learn about leadership, science, and people building their change into the world. The goal is to dig deeply into people who most of us wouldn’t normally ever get to hear. The Host of the show – Lowell Thompson- is a lifelong autodidact, serial problem solver, and founder of startups.

LINKS

Spotify: https://open.spotify.com/show/66eFLHQclKe5p3bMXsCTRH

RSS: https://www.learningwithlowell.com/feed/podcast/

Youtube: https://www.youtube.com/channel/UCzri06unR-lMXbl6sqWP_-Q

Youtube clips: https://www.youtube.com/channel/UC-B5x371AzTGgK-_q3U_KfA

Website: https://www.learningwithlowell.com/

Kelsey moody links

https://www.linkedin.com/in/kelsey-moody-phd-mba-55434421

Timestamps /show notes

00:00 Intro

00:30 How are ichor life sciences not out of business

02:30 why don’t more people copy his business model

04:40 Finding the right investors

08:10 Sales in biotech

10:05 approach to hiring, managing, etc 

11:20 Liquid liquid phase separation

16:00 Using phase separation 

18:40 Protein vs Phase 

22:24 Phase separation to find black swans 

21:25 downside to phase separation

24:00 Phase separation being incorporated into portfolio / building tools. 

27:11 Why choose phase separation / tool building

29:11 Future of ichor 

30:10 Missing to meet that future

31:30 Build the headquarters / USA

33:33 Will they need $100 million

36:10 Startups / biotech wasting money  

39:00 Continuity of vision / delusions / Moody in control 

39:50 Getting the most from his team / biggest struggle

43:25 innovation days

45:30 Breakdown of startups in portfolio / interventions they’re developing FanQ

49:20 How far from clinical trials Fanq

51:18 Lipid Nano Particle to deliver your Lysoclear enzyme FANQ

54:24 Lysoclear enzyme compared to other interventions  / macular degeneration

57:30 how will Lysoclear enzyme be applied elsewhere 

59:30 Functional rejuvenation / aubrey de grey / repair future

01:02:30 Criticism Roche is leading these Ph2a trials / FanQ

01:07:18 Aubrey de grey LEV robust mouse rejuvenation study at ichor / insane!

01:10:50 Surprising / relieved developments from mouse rejuvenation study

01:12:18 building a ginkgo bioworks biobank

01:14:30 Surprising legal document

01:15:03 When was Kelsey happiest in life

01:16:07 Big sacrifice as a founder

01:18:50 Bryan johnson blueprint protocol / health optimization 

01:20:33 Staying up to date.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.